Health
Researchers receive $5.1 million to expand clinical trial of drug to prevent ARDS in COVID-19 patients – News-Medical.Net
Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress s to expand the Phase II clinical trial at…
Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients were awarded $5.1 million in funding from the U.S. Department of Defense (DOD) to expand the Phase II clinical trial at The University of Texas Health Science Center at HoustonQ (UTHealth).
Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude…
-
General12 hours agoFarmers develop ‘autofill’ tech so agricultural robots can operate around the clock
-
Noosa News18 hours agoRevealed: 75 Qld suburbs you could afford to buy in if lending standards drop
-
General15 hours agoTrump mulling whether to fire US Fed chair Powell
-
Noosa News18 hours agoNowhere is growing like this corner of Queensland. It’s changing the political game